Author: Throne Biotechnologies
The world has seen a four-fold rise – in just 30 years– in Type 2 Diabetes cases (880 million according to the WHO 2024 report1) so new drugs (Ozempic, Wegovy) have emerged as novel long-term treatments.
According to the US CDC, 34 million Americans have Type 2 Diabetes, while 1.6 million are estimated to have (autoimmune-based) Type 1 Diabetes.
Meanwhile, a quieter, more important breakthrough has emerged for treating Type 1 Diabetes and other autoimmune conditions (with 50 million US cases). That groundbreaking work comes from Throne Biotechnologies of Paramus, NJ (US).
Throne’s innovation: Use cord blood stem cells to probe new ways to significantly treat Type 1 Diabetes plus a growing list of autoimmune conditions – from Long COVID to Crohn’s Disease.
The world has seen a four-fold rise – in just 30 years– in Type 2 Diabetes cases (880 million according to the WHO 2024 report1) so new drugs (Ozempic, Wegovy) have emerged as novel long-term treatments.
According to the US CDC, 34 million Americans have Type 2 Diabetes, while 1.6 million are estimated to have (autoimmune-based) Type 1 Diabetes.
Meanwhile, a quieter, more important breakthrough has emerged for treating Type 1 Diabetes and other autoimmune conditions (with 50 million US cases). That groundbreaking work comes from Throne Biotechnologies of Paramus, NJ (US).
Throne’s innovation: Use cord blood stem cells to probe new ways to significantly treat Type 1 Diabetes plus a growing list of autoimmune conditions – from Long COVID to Crohn’s Disease.
Stem cell therapy for autoimmune conditions – a game-changer?
Autoimmune diseases occur when the body’s immune system mistakenly attacks healthy cells, creating chronic inflammation and long-term damage. Conventional treatment simply targets symptoms, often using steroids to suppress immune activity.
Throne’s approach, however, uses its Stem Cell Educator (SCE) therapy. This deploys Cord Blood Stem Cells (CB-SCs) to recruit the patient’s own immune system, repairing and resetting that immune system and putting it back in balance. As a clinical stage company, Throne Biotechnologies is also an FDA-designated Regenerative Medicine innovator, a rare and key recognition for its continuing success in treating autoimmune disorders.
Developed by Dr. Yong Zhao, MD, Ph D and Founder and CEO of Throne, SCE Therapy uses human cord blood stem cells (CB-SCs) to modulate the vital immune functions. By design, the process helps CB-SCs reprogram defective immune cells, targeting the root cause of autoimmune and chronic inflammation-associated diseases.
“Our CB-SCs can target different compartments of the immune system, educating and correcting their dysfunctions at a fundamental level,” says Dr. Zhao. “This therapy has the potential to revolutionize autoimmune treatments, and we have over 20 years of clinical research to demonstrate this.”
The Stem Cell Educator treatment
Autoimmune diseases occur when the body’s immune system mistakenly attacks healthy cells, creating chronic inflammation and long-term damage. Conventional treatment simply targets symptoms, often using steroids to suppress immune activity.
Throne’s approach, however, uses its Stem Cell Educator (SCE) therapy. This deploys Cord Blood Stem Cells (CB-SCs) to recruit the patient’s own immune system, repairing and resetting that immune system and putting it back in balance. As a clinical stage company, Throne Biotechnologies is also an FDA-designated Regenerative Medicine innovator, a rare and key recognition for its continuing success in treating autoimmune disorders.
Developed by Dr. Yong Zhao, MD, Ph D and Founder and CEO of Throne, SCE Therapy uses human cord blood stem cells (CB-SCs) to modulate the vital immune functions. By design, the process helps CB-SCs reprogram defective immune cells, targeting the root cause of autoimmune and chronic inflammation-associated diseases.
“Our CB-SCs can target different compartments of the immune system, educating and correcting their dysfunctions at a fundamental level,” says Dr. Zhao. “This therapy has the potential to revolutionize autoimmune treatments, and we have over 20 years of clinical research to demonstrate this.”
The Stem Cell Educator treatment
Outcomes from Throne’s recent clinical trials show that SCE Therapy successfully creates lasting roads to relief for long-suffering patients:
As Throne Medical Director Dr. Boris Veysman says, Throne’s treatment goal is to modulate a body’s immune system so that the body “forgets” its autoimmunity.
Glancing ahead
CEO Dr. Zhao has high confidence in his therapy’s record of efficacy throughout clinical trials. In 2024, Throne also received the FDA’s “Regenerative Medicine Advanced Therapy” (RMAT) designation, a distinction shared only by a select number of pioneering therapies. This underscores FDA’s recognition of SCE’s potential to treat the unmet needs in regenerative medicine. RMAT status offers more benefits: It expedites development and regulatory support, accelerating the time when SCE therapy is available to patients in Europe and beyond.
Given its clinical outcomes, Throne sees growing potential for SCE Therapy becoming the new standard of care for immune-modulated conditions.
1 Note: Read here the World Health Organization’s (WHO) 2024 report on global diabetes.
- Type 1 Diabetes – Cord blood stem cells stop the autoimmunity and regenerate insulin-producing islet b cells, thereby slowing (or stopping) disease progression.
- Long COVID – Many Long COVID patients experience lingering immune dysfunction and sleeplessness. SCE therapy helps reduce inflammation, repair damaged tissues, and restore immune function — giving patients long-lasting symptom relief.
- Alopecia Areata – The SCE process regrows hairs, often throughout the body.
- Crohn’s Disease – Stem cells help heal the gut lining, reduce inflammation and improve digestive health (avoiding lifelong drugs and invasive treatments).
As Throne Medical Director Dr. Boris Veysman says, Throne’s treatment goal is to modulate a body’s immune system so that the body “forgets” its autoimmunity.
Glancing ahead
CEO Dr. Zhao has high confidence in his therapy’s record of efficacy throughout clinical trials. In 2024, Throne also received the FDA’s “Regenerative Medicine Advanced Therapy” (RMAT) designation, a distinction shared only by a select number of pioneering therapies. This underscores FDA’s recognition of SCE’s potential to treat the unmet needs in regenerative medicine. RMAT status offers more benefits: It expedites development and regulatory support, accelerating the time when SCE therapy is available to patients in Europe and beyond.
Given its clinical outcomes, Throne sees growing potential for SCE Therapy becoming the new standard of care for immune-modulated conditions.
1 Note: Read here the World Health Organization’s (WHO) 2024 report on global diabetes.